Vnitr Lek 2013, 59(12):1073-1080

The position of tiotropium in new treatment guidelines for chronic obstructive pulmonary disease

V. Koblížek
Plicní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta doc. MUDr. František Salajka, CSc.

Chronic obstructive pulmonary disease is a significant syndrome of internal medicine with serious health, social and economic impacts. Globally, tiotropium is the longest used and through the randomised studies the most examined representative of inhalation long-acting antimuscarinics. In routine practice, this treatment group is identified with a globally known abbreviation LAMA (or U-LAMA, U means ultralong-acting with dosing every 24 hours). Pharmacological agents of the LAMA (U-LAMA) group are included in a significant number of all important treatment guidelines. The Czech guidelines place these medicines into the first line of general medication - for all symptomatic patients, regardless of the stage, age and comorbidities. The article describes the role of LAMA (namely tiotropium) in the treatment of chronic obstructive pulmonary disease and also relevant evidence of the efficacy and safety of both tiotropium dosage forms (HandHaler and Respimat) in detail.

Keywords: chronic obstructive pulmonary disease (COPD); treatment guidelines; LAMA; tiotropium

Received: November 6, 2013; Accepted: November 17, 2013; Published: December 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Koblížek V. The position of tiotropium in new treatment guidelines for chronic obstructive pulmonary disease. Vnitr Lek. 2013;59(12):1073-1080.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364: 613-620. Go to original source... Go to PubMed...
    2. Hooper R, Burney P, Vollmer WM et al. Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project. Eur Respir J 2012; 39: 1343-1353. Go to original source... Go to PubMed...
    3. Koblížek V, Chlumský J, Zindr V et al. Chronic obstructive pulmonary disease in the light of new guidelines - brief summary of phenotypically oriented guidelines for nonpulmonary physicians. Vnitř Lék 2013; 59: 505-514. Go to PubMed...
    4. Miravitlles M, Soler-Cataluña JJ, Calle M et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery. Arch Bronconeumol 2012; 48: 247-257. Go to original source...
    5. Hronek M, Kovarik M, Aimova P et al. Skinfold anthropometry-the accurate method for fat free mass measurement in COPD. COPD 2013; 10: 597-603. Go to original source... Go to PubMed...
    6. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Updated 2013. 2013 Feb [cited 2013 Nov 2]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf.
    7. Lamprecht B, McBurnie MA, Vollmer WM et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest 2011; 139: 752-763. Go to original source... Go to PubMed...
    8. Malý M, Zvolský M, Rozborilová E et al. Respiratory Mortality in Czech and Slovak Republics in the year 2011. Stud Pneumol Phtiseol 2013; 73: 128-132.
    9. Vondra V Úmrtnost na CHOPN v letech 1996-2005 se zdvojnásobila. Stud Pneumol Phtiseol 2007; 67: 75.
    10. Institute of Medical Information Services. Tuberculosis and respiratory diseases 2011. 2012 Nov [cited 2013 Nov 2] Available from: http://www.uzis.cz/katalog/zdravotnicka-statistika/tuberkuloza-respiracni-nemoci.
    11. Hooper R, Burney P, Vollmer WM et al. Risk factors for COPD spirometrically defined from the lower limit of normal in the BOLD project. Eur Respir J 2012; 39: 1343-1353. Go to original source... Go to PubMed...
    12. Bryant J, McDonald V, Boyes A et al. Improving medication adherence in chronic obstructive pulmonary disease: a systematic review. Respir Res 2013; 14: 109. Go to original source... Go to PubMed...
    13. Qaseem A, Wilt TJ, Weinberger SE et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update for the ACP, ACCP, ATS and ERS. Ann Intern Med 2011; 155: 179-191. Go to original source... Go to PubMed...
    14. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease (updated) Clinical guidelines CG101. 2013 Mar [cited 2013 Nov 2]. Available from: http://www.nice.org.uk/CG101.
    15. Celli BR. Update on the management of COPD. Chest 2008; 133: 1451-1462. Go to original source... Go to PubMed...
    16. Czech Pneumological and Phthisiological Society. Guidelines for indication of home long term oxygen therapy 2013. 2013 Apr [cited 2013 Nov 2]. Available from: http://www.pneumologie.cz/odborne/doc/Standard%20DDOT-%20final.pdf.
    17. O'Donnell DE, Aaron S, Bourbeau J et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 2007; 14: (Suppl B): 5B-32B. Go to original source... Go to PubMed...
    18. Lange P, Marott JL, Vestbo J et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012; 186: 975-981. Go to original source... Go to PubMed...
    19. Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012. Go to original source... Go to PubMed...
    20. Anthoniesen NR, Skeans MA, Wise RA et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233-239. Go to original source... Go to PubMed...
    21. Lee PN, Fry JS. Systematic review of the evidence relating FEV1 decline to giving up smoking. BMC Med 2010; 8: 84. Go to original source... Go to PubMed...
    22. Troosters T, Molen T, Polkey M et al. Improving physical activity in COPD: towards a new paradigm. Respir Res 2013; 14: 115. Go to original source... Go to PubMed...
    23. Decramer M, Celli BR, Kesten S et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT) a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-1178. Go to original source... Go to PubMed...
    24. Mahler DA, D'Urzo A, Bateman ED et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilatation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012; 67: 781-788. Go to original source... Go to PubMed...
    25. Tashkin DP, Fabbri LM Long-acting beta-agonist in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010; 11: 149. Go to original source... Go to PubMed...
    26. Wedzicha JA, Decramer M, Ficker JH et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1: 199-209. Go to original source... Go to PubMed...
    27. Vogelmeier C, Hederer B, Glaab T et al. Tiotropium versus salmeterol for the prevention of exacerbation of COPD. N Engl J Med 2011; 364: 1093-1103. Go to original source... Go to PubMed...
    28. Calverley PM, Anderson JA, Celli BR et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789. Go to original source... Go to PubMed...
    29. Miravitlles M, Calle M, Soler-Cataluña JJ. Clinical phenotypes of COPD. Identification, definition and implications for quidelines. Arch Broncopneumol 2012; 48: 86-98. Go to original source...
    30. Kerstjens H, Engel M, Dahl R et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367: 1198-1207. Go to original source... Go to PubMed...
    31. Wells JM, Dransfield MT. Pathophysiology and clinical implication of pulmonary arterial enlargement in COPD. Int J Chron Obstruct Pulmon Dis 2013; 8: 509-521. Go to original source... Go to PubMed...
    32. Beeh K, Glaab T, Stowasser S et al. Characterization of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. Respir Res 2013; 14: 116. Go to original source... Go to PubMed...
    33. Hurst JR. Exacerbation phenotyping in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 184: 625-626. Go to original source... Go to PubMed...
    34. Izquierdo-Alonso JL, Rodriguez-Gonzálezmoro JM, de Lucas-Ramos P et al. Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD). Respir Med 2013; 107: 724-731. Go to original source... Go to PubMed...
    35. Nava S, Sturani C, Hartl S et al. End-of-life decision - making in respiratory intermediate care units: a European survey. ERS TASK FORCE. Eur Respir J 2007; 30: 156-164. Go to original source... Go to PubMed...
    36. Lanken PN, Terry PB, DeLisser HM et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med 2008; 177: 912-927. Go to original source... Go to PubMed...
    37. Celli BR, Thomas NE, Anderson JA et al. Effect of pharmacotherapy on the rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338. Go to original source... Go to PubMed...
    38. Jenkins CR, Jones PW, Calverley PM et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59. Go to original source... Go to PubMed...
    39. Laube BL, Janssens HM, Jongh FH et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011; 37: 1308-1331. Go to original source... Go to PubMed...
    40. O'Donnell DE, Flüge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840. Go to original source... Go to PubMed...
    41. Decramer ML Chapman KR, Dahl R et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013; 1: 524-533. Go to original source... Go to PubMed...
    42. Casaburi R, Kukafka D, Cooper CB et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809-817. Go to original source... Go to PubMed...
    43. Kesten S, Casaburi R, Kukafka D et al. Improvement in self-reported exercise participation with combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis 2008; 3: 127-136. Go to original source... Go to PubMed...
    44. Singh S, Loke YK, Enright PL et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2011; 342: d3215. Go to original source... Go to PubMed...
    45. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium the FDA's conclusions. N Engl J Med 2010; 363: 1097-1099. Go to original source... Go to PubMed...
    46. ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Tiotropium Respimat Pharmacokinetic Study in COPD[cited 2013 Nov 4] Available from: http://www.clinicaltrials.gov/ct2/show/NCT01222533.
    47. Wise RA, Anzueto A, Cotton D et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013; 369: 1491-1501. Go to original source... Go to PubMed...
    48. Matejovska-Kubesova H, Weber P, Meluzinova H et al. Senioři a kardiovaskulární medikace. Vnitř Lék 2011; 57: 561-570. Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.